Nine Malaysian hospitals to work with WHO for drug trials on COVID-19
By Akshay Kedari  Date: 2020-04-06

Nine Malaysian hospitals to work with WHO for drug trials on COVID-19

With the growing COVID-19 crisis, various initiatives are being taken worldwide where numerous organizations of various scale and are contributing as much as they can towards the efforts. The WHO, the biggest global authority responsible for international public health, is planning a solidarity trial to test various drugs that could help fight the coronavirus.

In a recent press release, the WHO, in collaboration with the Health Ministry of Malaysia, announced that the country has been selected to be a participant in the “Solidarity Trial”. Nine hospitals across Malaysia have been selected and would very soon initiate drug testing for coronavirus.   

Health Director-General, Datuk Dr. Noor Hisham Abdullah stated that the Health Ministry has expedited the process to conduct drug testing for the treatment of coronavirus patients. The trials would be conducted under the safety standards that are set by the National Pharmaceutical Regulatory Agency.

Dr. Noor further added that the participation of Malaysia in this global trial might help discover life-saving medicines to combat COVID-19 by evaluating their effectiveness and safety. Clinical Research Malaysia and Institute for Clinical Research of the Health Ministry of Malaysia would also help with the implementation of drug trials across the nation.

Queen Elizabeth Hospital, Sarawak General Hospital, Tengku Ampuan Afzan Hospital, Melaka Hospital, Kuala Lumpur Hospital, Sungai Buloh Hospital, Penang Hospital, Sultanah Bahiyah Hospital, and Tuanku Fauziah Hospital are the nine hospitals that have been selected from Malaysia to conduct trails of several drugs.       

Dr. Chow Ting Soo will lead the research and drug trials in Malaysia, and would also have access to a team of 16 Infectious Disease pharmacists and physicians working in their respective hospitals. Dr. Soo is an Infectious Disease Consultant in Penang Hospital.

The drug trials would primarily test the effectiveness of four different treatment protocols utilizing various combinations of five drugs which include Hydroxychloroquine, Chloroquine, Interferon beta, Lopinavir/Ritonavir, and Remdesivir.

Source credit: https://www.thestar.com.my/news/nation/2020/04/06/covid-19-nine-m039sian-hospitals-to-start-who-global-drug-trial

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...

RADCOM introduces automated assurance solution for 5G technology
RADCOM introduces automated assurance solution for 5G technology
By Akshay Kedari

5G technology has been in the headlines for quite a while. Next-generation technology has the potential to transform almost every sector across the world. However, as 5G becomes reality, it has become imperative for service providers to prevent degra...

Sprout to expand wellness solutions lineup by acquiring Vivametrica
Sprout to expand wellness solutions lineup by acquiring Vivametrica
By Akshay Kedari

Sprout, a Canadian company that focuses on delivering innovative solutions for workplace wellbeing, has recently announced the acquisition of predictive health data analytics firm, Vivametrica. According to reliable sources, Sprout plans to enhance t...

Uber halts decision to shift APAC headquarters from Singapore
Uber halts decision to shift APAC headquarters from Singapore
By Akshay Kedari

Uber Technologies Inc., the American ride-hailing giant, has reportedly halted the company’s decision to relocate its Asia Pacific headquarters from Singapore to Hong Kong until December 2022. Sources cite that the company’s decision was...

PCI Pharma extends global clinical supply-chain services in Europe
PCI Pharma extends global clinical supply-chain services in Europe
By Akshay Kedari

U.S. based biopharmaceutical and pharma outsourcing services company, PCI Pharma services has reportedly announced that it reached a noteworthy milestone through the development of COE (Clinical Center of Excellence) in Berlin. According to credible...